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1 BACKGROUND:  
1.1 MORTALITY BURDEN AND PHYSICAL COMORBIDITIES AMONG PEOPLE WITH MENTAL HEALTH 
CONDITIONS:  
According to the world health organization (WHO), mental health conditions are defined as set of 
diseases that are mainly characterized by abnormalities in thought, behaviour and emotion in a way 
that may hinder their effective interaction with other people (1). Furthermore, mental health 
conditions are clinically diagnosable disorders that may sustain for long period or demonstrate 
recurrent pattern during the life. Mental health conditions are considered universal disorders that 
affect people at wide range regardless their age and geographical location (2,3).  Around of 50% 
mental health condition including schizophrenia are most likely diagnosable by the age of 14 and 
years old age. People with major mental health conditions such as schizophrenia and depression 
experience around 40 to 60 % higher chances of premature death compared to the general 
population(1).  
Cardiovascular diseases have been reported to be a major cause of death in patients with mental 
health conditions (4,5). Patients with schizophrenia show an increased rate of mortality due to 
cardiovascular diseases (13). The aetiology of cardiovascular complications in people with mental 
health conditions is multidimensional in nature, which includes several aspects such as life style 
factors, genetic factors and cardiovascular related diseases. The high mortality that are observed in 
this population was suspected to be linked to the increased rate modifiable cardiovascular risk 
factors (5). Prevalence studies indicate that modifiable cardiovascular risk factors such as diabetes, 
abnormal lipid profile, glycemic abnormalities, weight gain, serious alterations in the cardiac-
conductivity (6), hypertension and insulin resistance , are highly prevalent in patients with psychotic 
illness such as schizophrenia and depression (5,7). Although, the exact underlining cause of 
cardiovascular complications in patients with mental conditions is not well defined (5), there is a 
growing body of evidence which have addressed the possible association between the use of 
antipsychotics, antidepressants and the increased incidence of cardiovascular disease (CVD) in 
people using these medications. However, the majority of previous work addressed several 
confounding factors other than the effect of the targeted psychotropic drugs for example life style 
and genetic factors. This makes difficult to build a conclusive estimation of the actual impact of 
antipsychotics and antidepressants on the prevalence of CVDs.   
1.2 ANTIPSYCHOTIC AND ANTIDEPRESSANTS AS INDEPENDENT RISK FACTORS FOR CARDIOVASCULAR 
AND METABOLIC COMORBIDITIES IN PEOPLE WITH MENTAL HEALTH CONDITIONS:  
One particular interest to researchers and clinicians is the increased risk of cardiovascular 
complications (CVCs) and their associated risk factors with the use of psychotropic medications. 
Evidence provided by Wu CS et al (6) and others (7) through the results of the review that was done 
to evaluate the cardiometabolic characteristics for individual psychotropic classes, which revealed 
that antipsychotic drugs and other psychotropic agents such as antidepressants have the potential 
to causes cardiovascular risk factors or accelerate pre-existing ones. The adverse effects on the 
cardiovascular system can be caused by different mechanisms which are beyond the focus of this 
section, however, this effect can be caused either by direct action on the heart or through indirect 
cascade of metabolic dysregulations which can finally lead to adverse cardiac events (8).  
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Antipsychotic medications are widely used in the management of schizophrenia and other mental 
health conditions. Antipsychotic drugs are classified into two major classes. The first class is known 
as typical antipsychotics or first generation antipsychotic drugs (FGAs). This group is characterized by 
their effectiveness in relieving positive psychotic symptoms of schizophrenia such as hallucinations. 
However, they have been proved to be less effective against negative symptoms, which lead to the 
development of the new generation of antipsychotic drugs which are known as second generation 
antipsychotic or atypical antipsychotic drugs (9). Second generation antipsychotic drugs are more 
effective than typical antipsychotic drugs in relieving negative symptoms, so the compliance to 
therapy would increase hence decrease frequency of relapse (10) 
Antidepressants on the other hand, are considered a typical intervention to manage people who 
suffer from depressive mood disorders and other psychotic disorders such as depressive 
schizophrenia. In the future, it is estimated that mortality due to cardiovascular diseases along with 
depressive diseases will be escalated globally (11,12). Moreover, some studies revealed that 
depressive disorders tend to be associated with more prevalence of cardiovascular risks (13). 
1.2.1 Antipsychotic medications:  
At normal therapeutic dose first generation antipsychotic drugs (FGAs) have been known to cause 
motor abnormalities mainly extrapyramidal symptoms (EPS) (9,10). Second generation antipsychotic 
drugs, on the other hand, have less motor side effects compared to the previous generation. 
Moreover, the extrapyramidal symptoms (EPS) caused by second generation antipsychotic drugs 
(SGAs) tend to be dose dependent with achievable therapeutic effect that is free of extrapyramidal 
symptoms (EPS), which makes second generation antipsychotic drugs (SGAs) more preferable over 
the first generation antipsychotic drugs (FGAs) (10). However, second generation antipsychotic drugs 
have similar cardiovascular risks that represented in their negative effects on the cardiac 
conductivity, vascular changes and metabolic homeostasis.  
1.2.1.1 Cardiovascular side effects of antipsychotic drugs:  
Antipsychotic drugs are known to cause cardiac arrhythmia as well as orthostatic hypotension 
(18). In healthy population, the QTc interval ranges from 380 to 450 milliseconds (ms) and this can 
vary according to patients’ age and gender. QT prolongation can be defined as > 450 to 460 ms 
increase above the normal physiologic range (14). Both generations of antipsychotics have the 
capability to cause electrocardiogram (ECG) changes (14). Epidemiologic studies (6,15) correlate this 
lengthen in QTc interval with the increased risks of sudden death that have been reported among 
patients using antipsychotic drugs. Antipsychotic drugs associated with this risk include but are not 
limited to haloperidol, olanzapine, quetiapine, risperidone and sulpiride (6). The arrhythmogenis 
effect caused by antipsychotic was reported with high doses of antipsychotic drugs, however, this 
effect can occur at normal therapeutic doses. Therefore, determining the need for regular ECG 
monitoring can be challenging. Furthermore, antipsychotic drugs have been reported to cause 
changes in blood pressure. Orthostatic hypotension is the most frequent vascular effect of 
antipsychotic drugs. Up to 40% of patients treated with antipsychotic reported to suffer from sudden 
drop of blood pressure at standing. Orthostatic hypotension can be defined either as ≥20 mmHg 
reduction in systolic blood pressure (SPB) or ≥10mm Hg decrease in diastolic blood pressure (DBP) 
after standing for 3 minutes (16). Notably, the hypotensive effect tend to occur at the early phase of 
psychotic treatment (16),  however, it is not clear wither this effect is dose dependent knowing that 
loading dose regiment is commonly utilised at the early stages of psychotic treatment. Besides, the 
orthostatic hypotensive effect have been proved to be common among elderly patients treated with 
antipsychotic therapy and orthostatic hypotension is general concern in old patients treated with 
antipsychotic drugs as risks of falls would be magnified. 
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1.2.1.2 Metabolic side effects of antipsychotic drugs:  
Weight gain is a major components of the metabolic dysregulations that caused by antipsychotic 
drugs (7,9) and its considered a major risk factor for cardiovascular diseases (CVDs). The effect of 
weight gain can vary among different antipsychotic classes (7,9), since it was more frequent with 
SGAs. Moreover, there is a hierarchical effect on the risks of weight gain among antipsychotics 
drugs, that has been conﬁrmed by different studies (7,9,17). Several clinical studies () showed that 
second generation antipsychotic drugs (SGAs) primarily clozapine and olanzapine demonstrate 
greater weight inducing effects compared to other antipsychotic drugs (15), in addition to other lipid 
associated risk factors such as dyslipidemias and insulin resistance. Some studies highlighted that 
specific patients characteristics such as age and degree of exposure to antipsychotic drugs may 
increase risks of weight gain (9). Young patients have been reported to be the most susceptible to 
metabolic dysregulations including weight gain. This is highly important when considering the fact 
that some mental health conditions such as schizophrenia and depression tend to develop at young 
age and may continue to progress in later life (18), and the antipsychotic induced weight effect have 
been suggested to be persistence and even be cumulative(19). This may indicate warning signs of 
increased risks of cardiovascular disorders due to obesity at early stages of life.  
Other metabolic dysregulations have been associated with the use of antipsychotic drugs such as 
dyslipidemias, which apparently associates with the body weight. Second generation antipsychotics 
mostly clozapine and olanzapine have been associated with the higher tendency to cause 
dyslipidemias mainly hyperlipidemia and hypertriglyceridemia (7).Hypertriglyceridemia induced by 
antipsychotics can be developed rapidly as the level of triglyceride (TG) can be doubled within two 
weeks after initiating the treatment with antipsychotics (7). Consequently, antipsychotic drugs have 
been reported to cause metabolic syndrome (MS). A cluster of abnormalities that associate with 
metabolic disturbances including central obesity, dyslipidemias,  plasma glucose abnormalities, and 
hypertension (20). Results from a prevalence study (21), reported a considerable increase in rate of 
metabolic syndrome among patients treated with antipsychotic drugs, as 40.2% of the participants 
were diagnosed to have metabolic syndrome. Some metabolic criteria that identify patients with 
metabolic syndrome (MS) have been previously addressed to be associated with the use of 
antipsychotic drugs and hence the increased risk for cardiovascular diseases and other metabolic 
conditions such as diabetes mullets (DM). Moreover, patients with metabolic syndrome (MS) have 
been reported to have high risks of developing cardiovascular and metabolic diseases such as 
coronary heart diseases and diabetes.   
1.2.2 Antidepressants medications: 
The exact pathophysiology between the cardiovascular events and depression still not well 
established. Amongst the suggested explanations is the potential role cardiovascular side effects of 
antidepressants that may adversely affect the outcomes of people suffering from cardiovascular 
disease (22). Several studies showed an accelerated rate of cardiac mortality among antidepressants 
users.  
1.2.2.1 Cardiovascular side effects of antidepressants 
With regard to the safety of antidepressants drugs, previous work that addressed the safety of 
antidepressants in people with cardiac diseases, highlighted the indirect role of antidepressants on 
reducing the cardiovascular risks by improving the depressive symptoms. For example, (28), 
selective serotonin reuptake inhibitors (SSRIs) class were mainly investigated according to their 
effectiveness in improving the cognitive symptoms in patients with depression and hence the 
general outcome on their health would improve accordingly. Certain classes of antidepressants 
primarily tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have been well 
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established for their tendency to negatively affect the cardiac conductivity which can lead to fatal 
arrhythmias (11,23). Additionally, the arrhythmogenic side effect of antidepressant drugs revealed 
to be dose dependent (24) who reviewed the causes of cardiovascular incidents form that can result 
from non-cardiac drugs. Hypertension was also reported with antidepressant drugs (7). In meta-
analysis study of the cardiovascular adverse effects of psychotropic drugs, antidepressants such as 
venlafaxine and imipramine significantly increased the diastolic blood pressure (DBP) by 1.2mmHg 
and 1mmHg respectively (25).  
1.2.2.2 Metabolic side effects of antidepressants:  
Notably, the majority of the available data regarding the metabolic effects of antidepressants 
focus on their effects on the weight, however controversy exist regarding the effects of 
antidepressants on weight gain. Some authors suggest that the increase in weight might result from 
the improvement of depression symptoms as a result of the improved appetite of the patient. 
However, others argued this view by claiming that weight gain can be a cumulative effect of 
antidepressant treatment since it tends to be common during the acute phase of treatment and may 
continue after treatment cessation (7). With respect to antidepressant drug classes, older classes 
such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MOAIs) have been 
reported to have cause weight gain more than other antidepressants classes (26). Results from 
meta-analysis to investigate the risks of weight gain associated with different antidepressant drugs, 
showed significant increase in weight from the baseline that range from 1.5kg, 1.7kg and 2kg caused 
by amitriptyline, mirtazapine and nortriptyline respectively over a 4–12-week period(27).  
Newer antidepressant classes were also associated with substantial effect on weight. Recent review 
that highlights the rate of significant weight gain and factors associated with weight gain among 
antidepressants treated patients, pointed out that mainly paroxetine and citalopram were 
associated with significant weight gain, while other newer antidepressants classes may be 
considered to have neutral effect (28). Notably, the weight gain induced by antidepressant drugs has 
been reported to be associated with the duration of treatment, since this effect tends to be heighted 
with the increase duration of treatment. Long phase trials (16–46 weeks)(29) that compared the 
weight changes among patients treated with nefazodone (n=523) and selective serotonin reuptake 
inhibitors (SSRIs) (fluoxetine, paroxetine, and sertraline; N = 513), demonstrate that around 8.3% of 
patients treated with nefazodone and 17% of patients treated with selective serotonin reuptake 
inhibitors (SSRIs) experienced more than 7kg increased in weight. This may indicate that the weight 
inducing effect of antidepressants can be cumulative. However, it is not clear wither the weight 
inducing effects of antidepressant drugs can be reversed after ceasing the antidepressant treatment.  
In addition, antidepressants have been reported to cause glucose dysregulations, major components 
of metabolic syndrome. In general, tricyclic antidepressants (TCAs) are the main class that reported 
to be associated with hyperglycaemic activities (7). Limited data are available regarding the effect of 
antidepressant drug on other metabolic abnormalities such as dyslipidaemias (7) and insulin 
sensitivity, regardless the strong evidence that was provided by the study that investigated the 
predictors for development of metabolic syndrome among depressive patients, which shows 
significant association between the use of antidepressants mainly tricyclic antidepressants (TCAs) 
and the risks for development of certain components of metabolic syndrome (MS) particularly 
dyslipedima and hypertension (95% CI, OR; 1.8 to 2.57), consequently increased risks of metabolic 
syndrome (MS)(30).   
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1.2.3 Clinical implications:  
Recent review of the cardio metabolic side effects of psychotropic drugs showed a considerable 
variation in the metabolic effects among the different psychotropic drug classes. Currently, a head to 
head comparison between cardiovascular and metabolic side effects causes by different 
psychotropic medications (i.e. both antipsychotics and antidepressants in this context) is lacking. 
According to the review, the weight inducing effects that caused by antidepressants is considered 
lower than the effect induced by antipsychotics. For example, antidepressants tend to cause a 
relatively low increase in body weight, around 1.5-2 kg over 4 to 12 weeks period. In the contrary, 
the weight inducing effect of antipsychotic drugs was higher than the effect produced by 
antidepressants as they were reported to cause more than 7 kg raise in weight from the baseline 
after only 4 weeks treatment period (31).  Regarding this difference it is essential to appreciate  that 
the utilisation of co-treatment regimen with antipsychotic and antidepressants is a common practice 
in mental health (32), which can result in substantial underestimation of the synergism effect that 
can result from this combination.  
In practice, when considering treatment with antipsychotic drugs, the use of single agent 
antipsychotic is more preferred over the use of combined antipsychotic therapy (33). However, 
resistance to antipsychotic treatment is a common problem among patients treated with 
antipsychotics. According to the National Institute of Health and Care Excellency (NICE) (34), atypical 
antipsychotic drugs  mainly clozapine is preferred when response to first line antipsychotic therapy is 
lacking. By outweighing the risks of using drug with significant cardiovascular effects against the 
benefits of having better symptoms control, measures to reduce the adverse effects of the drug can 
be applied. As previously mentioned, combination therapy with antipsychotic drugs is not 
preferable, however, large proportion of patients with mental health conditions are treated with 
more than one antipsychotic drugs (15) Antipsychotic can be used in combinations with other 
psychotropic drugs for example antidepressants. Since psychotic symptoms can be manifested as 
depression, antidepressants can be considered to alleviate the depressive symptoms and improve 
the overall clinical outcome. Paradoxically, most preclinical and clinical trials on cardiovascular side 
effects of antipsychotic drugs and their associated risk factors focus on the effects of exposure to a 
single psychotropic agent.  
Antidepressant drugs on the other hand, are considered mainly in patients experiencing moderate to 
severe depressive symptoms (26). Furthermore, tricyclic antidepressants (TCAs) are not considered a 
first line option in the treatment of depression (35) since the introduction of the newer 
antidepressant classes such as selective serotonin re-uptake inhibitors (SSRIs). Owing to their 
effectiveness in improving depressive symptoms along with their relatively safe cardiac profile. This 
was supported by the results of a meta-analysis that shown that selective serotonin reuptake 
inhibitors (SSRIs) have significantly lowered the level of depressive symptoms compared to the 
placebo. Similar results were found by number of trials that studied the efficacy of selective 
serotonin reuptake inhibitors (SSRIs) on relieving depressive symptoms although significance was a 
major issue in these studies (36). However, the use of other antidepressant classes for example 
tricyclic antidepressants (TCAs) remain a considerable option when response to the first line class 
(SSRIs) is lacking. Recent advances in management of depression (32), support the use of augmented 
therapy with antipsychotic drugs in the management of refractory depressive episodes. As shown by 
the results of the meta-analysis that investigated the effectiveness of combined therapy of 
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antidepressants and antipsychotic in treating patients with depression, augmented therapy with 
antipsychotic was superior to treatment with conventional antidepressants mono-therapy (32).  
1.3 CURRENT PRACTICES IN MANAGING CARDIOVASCULAR CO-MORBIDITIES ASSOCIATED WITH 
ANTIPSYCHOTICS AND ANTIDEPRESSANT DRUGS: 
As suggested by many studies(37,38) early intervention is crucial to compensate cardiovascular 
complications that can be induced by antipsychotic drugs. Previously, there was no clinical guidance 
for health care providers that assist clinical monitoring of cardiovascular or metabolic side effects of 
psychotropic drugs. Consequently, prescribers relied mainly on their knowledge along with their 
professional experience. Based on the results from The Clinical Antipsychotic Trials of Intervention 
Effectiveness CATIE (21), the European Psychiatric Association (EPA)(5) in collaboration with the 
European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) 
have published a statement which aims to improve physical health care for mentally ill people. The 
intention was to support the need for regular monitoring and screening of cardiovascular diseases 
and their risk factors among people taking antipsychotics and antidepressants (5).  
In order to maximise screening and monitoring among patients treated with psychotropic drugs, 
several strategies have been introduced in practice aiming to minimize cardiovascular and metabolic 
side effects that can be caused by psychotropic medications. These strategies range from simple act 
such as adding drugs that can reverse or attenuate the adverse metabolic effects of psychotropic 
drugs to include more complicated behaviour for example adopting a healthy life style (9,31,39). 
Generally ,strategies can be divided into: pharmacological and non-pharmacological (40).   
In the context of mental health conditions, non-pharmacological interventions focus mainly on 
behavioural changes, in which affected people adopt certain measures for example life style 
modifications and educational programs. These interventions have been intended mainly to improve 
physical health in patients with mental health conditions. However, methodological variabilities such 
as sample size, duration of interventions and differences in intervention approaches themselves 
make it difficult to make conclusive estimation of their effectiveness. Pharmacological interventions, 
on the other hand, are strategies refer to acts that concern the use of medications. It may include 
proper selection of medication, switching between drugs and the use of adjunctive agent. Other 
forms of pharmacologic interventions such as screening and monitoring of cardiovascular side 
effects have been addressed in several trials (41–43).  
The selection of medication with preferable safety profile can be applied in patients with 
increased risks for a particular side effect. It includes the proper selection of drug dose and dosage 
formulation. Switching to a safer drug can be considered when adverse drug effect is suspected (44) 
or adjunctive drug can be added to attenuate or reverse the side effect of a concomitant agent. Few 
studies have considered switching for medication with favourable side effects profile as a major 
intervention to minimize the cardiovascular side effects of the utilized antidepressant drugs (45). 
Results of a review that investigated the different interventions to manage weight gain and 
metabolic disturbance in patients taking antipsychotic drugs (31) suggest that pharmacologic 
interventions primarily, switching between medications along with choosing the proper drug, are 
considered the most effective strategies to minimise weight gain. This is particularly useful when 
early non-pharmacological intervention is inadequately effective. However, even when physical 
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health issues are developed, evidence indicates that may health care professionals tend to be 
hesitance to switch to psychotropic with better side effects profile. This indicate an urgent need to 
identify factors that hinder the application of pharmacological interventions in patients treated with 
psychotropic drugs.    
So far, the majority of the proposed strategies to manage cardiovascular and metabolic side 
effects of psychotropic drugs focus on utilising non-pharmacological approaches. Such strategies are 
mainly based on behavioural modifications that encourage subjects to adopt behavioural changes 
which have positive impact on their life. An example of this, programs that are designed to aid 
weight management and smoking cessation (46). Furthermore, the majority of the proposed work 
focus on managing weight gain and physical health of patients treated with antipsychotic agents.   
Number of trials have focused on pharmacological interventions primarily the ones that lessen or 
antagonise that weight inducing effect of antipsychotic drugs (anti-obesity agents). Among the most 
commonly investigated agents are metformin and nevertheless, the safety and the clinical efficacy of 
some of the proposed anti-obesity drugs have not been established yet. Nevertheless, other forms 
of pharmacologic interventions such as switching between medications are not extensively 
investigated in the literature. Therefore, it is difficult to rely on this results if we considered that 
other potential effective approaches such as adding adjunctive drug and switching to safer drug may 
not be properly undertaken in real practice.  
1.4 WHY IT IS IMPORTANCE TO CONDUCT THIS REVIEW?  
There is no clear data from systematic reviews and meta-analysis regarding the prevalence of 
cardiovascular and metabolic comorbidities and their predisposing factors among patients with 
mental diseases which are associated with the use antipsychotic and antidepressants drugs. As 
indicated by several epidemiological studies (45) the prevalence of schizophrenia and depression 
continues to increase, which indicates a potential rise in the prescribing patterns of psychotropic 
medications worldwide. Furthermore, despite existing guidelines and recommendations, many 
antipsychotic and antidepressant drug-treated patients are not adequately assessed for easily 
measurable metabolic and cardiovascular risk factors, such as dyslipidemias and blood pressure (38). 
Most evidence points out that metabolic and cardiovascular comorbidities in people using 
antipsychotic and antidepressant medications are underdiagnosed. For instance, data generated 
form CATIE trial (41), which aimed to examine a multitude of variables in patients with schizophrenia 
that increases the incidents of metabolic syndrome (MS), demonstrate a significant variation in the 
level of management among elements of metabolic syndrome (MS). This included lower rate of 
screening and treatment of major cardiovascular risk factors such as hypertension and dyslipidemias, 
however, the study did not highlight any possible reasons for this low rate of treatment among the 
targeted population. Barriers to effective interventions in practice include resisting behaviour of 
patients with mental health conditions, time constrain and the availability of the necessary 
equipment may have possible impact.  
1.4.1 Rational of the review: (purpose statement)  
As proposed above, in order to alleviate cardiovascular and metabolic complications, which can 
be caused or aggravated by antipsychotics and antidepressants medications, careful follow-up with 
routine monitoring of cardiovascular disease and its related risk factors side effects at early stages 
might facilitate successful management of the complications and hence provide better prognosis. In 
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order to accomplish that, representative epidemiological data are critical in order to estimate the 
impact cardiac and metabolic related side effect of, mainly antipsychotics and antidepressants, on 
public health. Beside it is important to review the nature and effectiveness of interventions aimed to 
monitor and manage the cardiovascular and metabolic side effects of these medicines.  
1.4.2 Objectives of the study:  
 To identify the prevalence and incidence of cardiovascular and metabolic side effects in 
patients taking antidepressants and antipsychotic medications.  
 To identify the nature of interventions and their effectiveness around assessment, 
screening, monitoring, management cardiac and metabolic side effects of antipsychotics 
medications. 
 To identify the extent to which patients taking antidepressants & antipsychotics are 
assessed, screened, monitored and managed for cardiac and metabolic side effects. 
 To explore the perspectives of health care providers regarding the assessment, screening, 
monitoring and management of cardiac and metabolic side effects in patients taking 
antipsychotic or antidepressant medications.  
 To explore patients’ perspectives regarding the assessment, screening, monitoring and 
management of cardiac and metabolic side effects related to the use of antipsychotic and 
antidepressant medications.  
1.4.3 Review questions: 
 What are the incidence and prevalence of cardiac and metabolic complications that are 
correlated to the use of antipsychotic and antidepressant medications?  
 What are the different interventions to manage cardiovascular and metabolic side effects of 
antipsychotic and antidepressant medications that have been proposed in the literature?  
 Is there current evidence which support the effectiveness of regular assessment, screening 
and monitoring of cardiac and metabolic side effects of antipsychotic and antidepressant 
medications?   
 How often patients using antidepressant or antipsychotics are assessed, screened, monitored 
and for cardiac and metabolic risk? 
 What are the possible barriers for assessing, screening and monitoring the targeted side 
effects in patients using antipsychotics and antidepressants?  
2 METHODS: 
2.1 REPORTING GUIDELINES:  
The review protocol has been drafted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis (PRISMAP) statement (47). The review will be conducted as 
per the Cochrane guideline for systematic reviews (48) and Centre for Review and Dissemination 
(CRD) (49). Reporting of the review including results of the literature searching, screening, data 
extraction and the applied inclusion and exclusion criteria will conform to Preferred Reporting Items 
for Systematic Reviews and Met-Analysis (PRISMA) statement and checklist. This review will be part 
of a dissertation for a doctoral degree.  Eligibility criteria for inclusion: 
2.1.1 P: Populations 
 P 1: Adult patients aged ≥ 18 years old. 
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 Using one or more antipsychotics drugs or antidepressant therapy or a combination, for 
mental health conditions. 
 P2: Health care professionals involved in the care of the patients.  
 P2: Patients prescribed antipsychotics/antidepressants for mental health conditions  
Special inclusion criteria for studies to be selected for the prevalence purpose:  
 P3: patients of all ages receiving antipsychotics or antidepressants or both.   
2.1.2 I1: Interventions 
Interventions related to the assessment, screening, monitoring of cardiac and metabolic side effects 
related to antipsychotic and antidepressants.  
2.1.3 I2: Phenomena of Interest  
Views, experiences, behaviors of health care professionals and patients regarding the assessment, 
screening and monitoring of cardiac and metabolic side effects of the antipsychotics and 
antidepressants.  
2.1.4 O: Outcomes measures  
2.1.4.1 Primary outcomes:  
- Incidence or prevalence of cardiac or metabolic side effects of antipsychotics and 
antidepressants.  
- Nature of interventions that are proposed in the literature for example: pharmacological and 
non-pharmacological interventions. 
- Improvement or worsening of pre-existing cardiac or metabolic condition induced by 
antipsychotics and antidepressants.  
- Experience of patients receiving the interventions, for example: Patients’ satisfaction with 
care provided to manage cardiovascular and metabolic complications of antipsychotics and 
antidepressants.  
- Perspectives of health care providers regarding the delivery of care for example, barriers and 
facilitators to screening or management of cardiovascular side effects and their associated 
risk factors in patients using antipsychotics and antidepressants.  
2.1.4.2. Secondary outcomes:  
- Any other patient-reported outcomes other than symptom improvement for example their 
quality of life.  
- Hospitalisation or re-admission primarily related to cardiac or metabolic complications in 
patients prescribed antipsychotics and antidepressants.  
- Health care professionals and patients’ awareness, views and experiences of the 
cardiovascular and metabolic risks associated with the use of antipsychotics and 
antidepressants. 
2.1.5 C1: Context  
- Patients with mental health conditions using antipsychotics or antidepressants as major 
treatment for the primary condition (depression or psychosis).  
- Any clinical settings. 
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2.1.6 C2: Condition  
- Prevalence or incidence of cardiovascular and metabolic side effects and their risk factors in 
patients diagnosed with mental health conditions using mention the two classes of drugs.  
2.1.7 S: Study design:  
All designs that reported either incidence, prevalence or interventions to manage cardiovascular side 
effects of antipsychotics or antidepressants medications will be included for the review, however, 
studies will be excluded if they meet one of the following exclusion criteria:  
- Case reports. 
- Literature reviews.  
- Discussion and view point studies. 
- Grey literature 
- Abstract only publications.  
SEARCH LIMITATIONS: English language only, full text publications and studies focused on human, 
date limit Studies from year 2003 (last 15 years) and onward will be searched (2003). This date limit 
also coincides with the warring statements that issued by the the Food and Drug Administration 
(FDA) regarding the increased risks of diabetes induced by second generation antipsychotic drugs 
(50).   
2.2 SEARCH STRATEGY  
2.2.1 Information sources:  
2.2.2 Electronic sources:  
The following databases will be searched in order to identify for relevant literature including:  
 EMBASE  
 MEDLINE 
 PubMed 
 Cochrane Central Register of Controlled Trials 
 PsycINFO  
 CINAHL 
2.2.3 Searching additional sources to locate relevant literature:  
 Personal contact: researchers will be contacted if necessary to gain information for 
clarification purposes and access to raw material when needed.  
 Cross-referencing of bibliographies: reference list of the identified relevant studies will be 
scanned including reviews and primary studies.  
2.2.4 List of Search terms:  
The search strategy combines 4 facets of search terms: 
 Antipsychotic and antidepressants medications. 
 Cardiovascular and metabolic related side effects. 
 Intervention  
 Prevalence  
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A scoping search will be undertaken against each database to inform how the search terms are being 
be translated in each database and hence identify the corresponding text words in each database 
(51). After that they will be tested for their sensitivity to locate the key papers that the researcher is 
aware of, along with relevant articles which are consistent with the inclusion criteria just before 
applying the search in all the selected search engines. An extended list for the search terms will be 
provided in supported document (appendix) and they will be adapted as required for each 
databases. The search will be conducted in three separate stages in order to fulfil each objective of 
the study by recovering the relevant articles for per objective.  
2.3 STUDY SELECTION PROCESS: 
A random testing will be conducted to check the eligibility criteria before running the search for 
standardization purpose (52).  This process will be applied on the first 100 identified articles and the 
eligibility criteria will be revised as necessary. A two stages approach technique will be applied which 
involves the analysis of the title, abstract in the first stage then full text (51). Besides, the references 
of the identified articles will be screened for caching any relevant papers. The selected articles will 
be uploaded into online data collection form Rayyan QCRI. The selected inclusion criteria will be 
applied to the eligible articles. Titles and abstract will be reviewed and screened independently by 
two reviewers. Conflict regarding the results will be resolved by discussion or a third review if the 
agreement cannot be achieved. For missing data or unclear information, contact with primary 
investigator will be made as necessary. After duplicates removal, full texts of all the eligible studies 
will be uploaded into referencing manager software (MendeleyR) where they will be assessed further 
using a piloted check list of the eligibility criteria the PICOCS and the PIC/O. Any conflicts regarding 
the appropriateness of the selected articles will be sorted by team discussion. The same process will 
be applied for the full-text screening step.  
2.4 ASSESSMENT OF METHODOLOGICAL QUALITY: 
Articles selected for retrieval will be assessed for quality before final data extraction process and 
specific-design study tools will be employed for this purpose. Quality of the studies will be appraised 
using standardized critical appraisal instruments from the Joanna Briggs Institute Assessment and 
Review Instrument (JBI) (53), while the risk of bias in each study and across studies will be assessed 
using the Cochrane EPOC tool (54).  
2.5 DATA EXTRACTION: 
For each study that meet the inclusion criteria, data will be extracted by two authors, who will be 
working independently. Data will be extracted using standard form that was created based on study 
aim and objectives. The following data will be extracted  
 Study characteristics: authors, date, settings, country of origins and sample size.  
 Patient characteristics: demographic data (age, gender, body weight, height, diseases 
status, drug regiment (mono vs combined drug regiment), type of antipsychotic prescribed, 
co-comorbidities that could affect the outcome.   
 
 Outcomes of interest:  
 Quantitative outcomes:  
 Intervention characteristics’: type of intervention, exposure characteristics including the 
duration, frequency, intensity and health care professionals involved.  
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1. Outcomes for intervention effectiveness to reduce cardiovascular and metabolic 
side effects of the targeted drugs. For example, number of patients screened per 
visit, patients mean changes form baselines measures or during follow-up period 
and improvement of quality of life.  
2. All causes of mortality and readmissions due to cardiovascular side effects of 
antipsychotic and antidepressants drugs such as number of deaths or readmissions 
after applying the interventions.  
 Prevalence outcomes:  
1. Outcomes for prevalence or incidence of cardiovascular and metabolic related 
factors such as (n: %) patients affected.  
 
 Qualitative research finding represented as themes metaphors or categories that will be 
extracted.  
2.6 SYNTHESIS OF THE RESULTS:  
For the mixed method approach, the model will be applied in this review will rely on the “building 
and testing” concept (55).   
2.6.1 Quantitative data:  
Prevalence of cardiovascular and metabolic related complications in patients using antipsychotics 
and antidepressants and Interventions to reduce cardiovascular and metabolic complications of 
antipsychotics. We will enter relevant data information into table of the included studies. Meta-
analysis will be conducted when suitable, however, it is anticipated to result in methodological 
heterogeneity due to the wide variety of included studies in this case, narrative synthesis will be 
adopted.  
2.6.2 Qualitative data: Practitioners and patients prospective 
Thematic synthesis will be used to synthesis qualitative data into systematic categories [36]. The 
results of the qualitative synthesis will be utilized to generate recommendations and to provide any 
explanations for the results obtained from the quantitative data.  
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